• Set Text Size  

COVID-19 Resource Center

CDC Provides Guidance on COVID-19 Vaccine – Mixing Doses and Immunocompromised Patients

(Updated January 15, 2021) There is new information from the CDC concerning COVID-19 vaccines. The CDC says that the vaccines “may be administered to persons with underlying medical conditions who are not allergic or have no contraindications to vaccination.”


“Clinical trials demonstrated similar safety and efficacy profiles in persons with some underlying medical conditions, including those that place them at increased risk for severe COVID-19, compared to persons without comorbidities. Information on groups with specific underlying medical conditions is included below,” according to the CDC. The organization also strongly recommends against mixing doses of several different COVID-19 vaccines.

Read this very informative article from the CDC below.



MGFA Official Statement on the COVID-19 Vaccine for the MG Community

(Updated on December 26, 2020)

There are multiple vaccines for Covid-19 currently being developed. Receiving a vaccine for Covid-19 and following existing public health measures will reduce the likelihood of contracting the virus.  The vaccine will also reduce the spread of disease from one person to another. In the United States, vaccines manufactured by pharmaceutical companies Pfizer and Moderna were approved by the U.S. Food & Drug Administration (FDA). These are non-live vaccines that use modified RNA.

These vaccines were tested in people age 12 to 85 years. The majority of study subjects did not have underlying medical conditions.  Patients with autoimmune conditions, like myasthenia gravis, were not included in the testing of these vaccines to date. The most common side effects for people enrolled in the vaccine study were pain at the injection site, fever, chills, and muscle aches. In some cases, these side effects lasted for a few days. There is no risk of developing Covid-19 infection from the vaccine.

At this time, we think that these two Covid-19 vaccines will be recommended for patients with autoimmune conditions like myasthenia gravis and for those patients who take medications that suppress the immune system. The Covid-19 pandemic has severely affected people with some underlying medical conditions. It is unknown at this time whether myasthenia gravis (MG) or treatments for autoimmune MG increase the risk of contracting Covid-19 or experiencing more severe disease. However, like with other viruses, getting sick with a Covid-19 infection can bring on a MG exacerbation or crisis. We suggest that patients discuss the Covid vaccine with their neurologist and primary care provider.

Covid-19 vaccines will be distributed by each state according to guidance from the Centers for Disease Control.  Certain groups, such as health care workers, nursing home residents, and those with underlying medical conditions, are expected to receive the vaccine earlier in the distribution process.  We do not yet know where patients with myasthenia gravis and those with other autoimmune conditions will be placed in the vaccination priority list.  In the United States, each state’s health department website will have further information on distribution plans as they become available. It is important to stay in contact with your physicians and monitor your state health department guidelines as the vaccination process unfolds.

Links to a Selection of Published Studies on COVID-19 Vaccines


Centers for Disease Control & Prevention (CDC) Vaccine Webpage

CDC vaccination webpage is a valuable resource on vaccine information. This page also links to other strong resources from the CDC and the World Health Organization (WHO). 



Research survey for rare disease patients and their families about impacts of COVID-19

MGFA Published Survey

How is the novel coronavirus pandemic impacting people with rare diseases and their families? Complete the 20-minute research survey from home or learn more at this link. The Rare Diseases Clinical Research Network (RDCRN) is conducting this study. The network is funded by the National Institutes of Health. It includes 23 research teams working to advance diagnosis and treatment of groups of rare diseases. The Myasthenia Gravis Foundation of America and Conquer MG partners with RDCRN through its work with the Myasthenia Gravis Rare Disease Network (MGNet).


MGNet Webinar- "Myasthenia Gravis and the COVID-19 Epidemic: Things for you to know" 

MGFA Program

Presenters: Hana Axelrod, MD, MPH; Henry J. Kaminski, MD; Helen Girma, George Washington University Department of Neurology
We are pleased to share that the MGNet webinar, “MG and COVID-19: Things for you to Know” has been recorded and is available for viewing. We apologize for any technical difficulties in registering or participating in the webinar on March 18.

To view the recording of this webinar, please see here


COVID-19 (Coronavirus)- General Information and Management 

MGFA New Resources

March 2020

Due to the recent news regarding COVID-19 (coronavirus), we are providing some guidance around COVID-19, as well as reliable sources for information. See more information here


Centers for Disease Control & Prevention (CDC) website:



World Health Organization (WHO) website:



United States Food & Drug Administration (FDA) website:







A World Without MG